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A B S T R A C T
Alterations in the NRF2/KEAP1 pathway result in the constitutive activation of NRF2, leading to the aberrant
induction of antioxidant and detoxification enzymes, including NQO1. The NQO1 bioactivatable agent β-la-
pachone can target cells with high NQO1 expression but relies in the generation of reactive oxygen species
(ROS), which are actively scavenged in cells with NRF2/KEAP1 mutations. However, whether NRF2/KEAP1
mutations influence the response to β-lapachone treatment remains unknown. To address this question, we
assessed the cytotoxicity of β-lapachone in a panel of NSCLC cell lines bearing either wild-type or mutant KEAP1.
We found that, despite overexpression of NQO1, KEAP1 mutant cells were resistant to β-lapachone due to en-
hanced detoxification of ROS, which prevented DNA damage and cell death. To evaluate whether specific in-
hibition of the NRF2-regulated antioxidant enzymes could abrogate resistance to β-lapachone, we systematically
inhibited the four major antioxidant cellular systems using genetic and/or pharmacologic approaches. We de-
monstrated that inhibition of the thioredoxin-dependent system or copper-zinc superoxide dismutase (SOD1)
could abrogate NRF2-mediated resistance to β-lapachone, while depletion of catalase or glutathione was in-
effective. Interestingly, inhibition of SOD1 selectively sensitized KEAP1 mutant cells to β-lapachone exposure.
Our results suggest that NRF2/KEAP1 mutational status might serve as a predictive biomarker for response to
NQO1-bioactivatable quinones in patients. Further, our results suggest SOD1 inhibition may have potential
utility in combination with other ROS inducers in patients with KEAP1/NRF2 mutations.
1. Introduction
It is estimated that 38% of lung squamous cell carcinomas (LuSC)
and 18% of lung adenocarcinomas (LuAD) harbor mutations in Nuclear
factor erythroid 2-related factor 2 (NRF2), or its negative regulator
Kelch-like ECH-associated protein 1 (KEAP1) [1–3], making this
pathway one of the most commonly mutated in non-small cell lung
cancer (NSCLC). The transcription factor NRF2 acts as the primary
cellular barrier against the deleterious effects of oxidative stress by
regulating the expression of cytoprotective genes. In healthy tissues,
KEAP1 binds to and harnesses the activity of NRF2, thereby promoting
NRF2 ubiquitination and destruction by the proteasome [4–6]. Loss-of-
function mutations in KEAP1 and gain-of-function mutations in NRF2
found in NSCLC abolish this control and lead to constitutive NRF2 ac-
tivity [1,7–9]. Cancer cells that hijack NRF2 activity are equipped with
a reinforced cytoprotective system through the induction of antioxidant
and drug detoxification pathways, thereby rendering them resistant to
oxidative stress and chemo/radio-therapy [10–12].
High expression of the detoxification enzyme and bona fide NRF2
target gene NAD(P)H:quinone oxidoreductase 1 (NQO1) is a distinct
biomarker of NRF2/KEAP1 mutant NSCLC tumors. NQO1 is a cytosolic
flavoprotein that catalyzes the two-electron reduction of quinones into
hydroquinones in an effort to hamper oxidative cycling of these com-
pounds [13,14]. Although NQO1-dependent reduction of quinones has
been historically defined as a major detoxification mechanism, a
number of quinones induce toxicity following NQO1 reduction [15–19].
The mechanism behind this paradox relies on the chemical properties of
the hydroquinone forms. Unstable hydroquinones can be reoxidized to
the original quinone by molecular oxygen, which leads to the formation
of superoxide radicals. As the parent quinone is regenerated, the cycle
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Fig. 1. Aberrant activation of NRF2 increases resistance to β-Lapachone treatment.
*Please note that, for survival assays, cells were exposed to β-lapachone for 2 h, after which medium was replaced and cell viability was assessed 48 h after treatment
using CellTiter-Glo (D) or crystal violet staining (F,G). Western blots included in Fig. 1C, S3B and S4E are a reprobing of the same blot and share the loading control
(tubulin).
(A) Schematic representation of β-lapachone redox cycling. NQO1 catalyzes the two-electron reduction of β-lapachone to a hydroquinone form, which can spon-
taneously reoxidize, leading to the formation of superoxide radicals. (B) NQO1 mRNA expression in healthy lung tissue, lung adenocarcinomas (LuAD) and lung
squamous cell carcinoma (LuSC). NQO1 mRNA expression in tumors was subdivided according to the KEAP1/NRF2 mutational status. One-way ANOVA statistical
test was performed to compare groups. LuAD: P-value ANOVA summary<0.0001; Tukey's multiple comparison test Normal Vs WT (0.004, **) Normal vs MUT
(< 0.0001, ****). LuSC: P-value ANOVA summary< 0.0001; Tukey's multiple comparison test Normal Vs WT (0.0212, *) Normal vs MUT (< 0.0001, ****). (C)
Western blot analyses of NRF2, NQO1 and Tubulin expression in a panel of wild-type (WT) and mutant (MUT) KEAP1 NSCLC cells. Note that Calu-3 cells harbor a
polymorphic variant of NQO1 (NQO1*3, 465C < T). (D) Survival assays of KEAP1 wild-type (WT) and KEAP1 mutant (MUT) NSCLC cell lines exposed to β-
lapachone alone (left) or in combination with the NQO1 inhibitor dicoumarol (right). Cells were treated with vehicle (< 0.1% DMSO) or the indicated concentrations
of β-lapachone alone or in combination with dicoumarol (50 μM). KEAP1WT cells: H2009, H1299, H1581, H1975, H1993, H2087, H2347 and H441. KEAP1MUT cells:
A549, H460, H1792, H2127, H1944, HCC15, H322. Data presented as mean ± S.D. P-values KEAP1 WT vs MUT β-lap 2 μM = 0.0081 (**), 3 μM = 0.0002 (***),
4 μM= 0.0014 (**), 5 μM= 0.0314 (*) were calculated using unpaired t-tests. (E) Oxygen consumption rates of a panel of KEAP1 WT and MUT NSCLC cells exposed
to 2 and 3 μM of β-lapachone alone or in combination with 50 μM of dicoumarol for 117 min. KEAP1WT cells: H1299, H1581, H1975, H441, H2347, H2087.
KEAP1MUT cells: A549, H2172, H1944, H460, HCC15, H1792. Data presented as mean ± S.D. P-values KEAP1WT basal vs β-lapachone 2 μM (0.0007, ***) and 3 μM
(0.0006, ***) and KEAP1MUT basal vs β-lapachone 2 μM (0.0179, *) and 3 μM (0.0029, **) were calculated using a paired t-test statistical analysis. (F) H1299 cells
(KEAP1 WT) were infected with an empty vector (Control) or a virus coding for the expression of NRF2 T80K, KEAP1 wild-type or KEAP1 C273S. Left, Western blot
analyses of NRF2, Flag (for KEAP1 detection), NQO1 and actin (loading control). Right, survival assays of cells exposed to β-lapachone. (G) Western blot (left) and
survival assays (right) of H460 (KEAP1 MUT) infected with virus coding for shRNAs against NRF2 (shNRF2) or an shRNA control.
L. Torrente, et al. Redox Biology 30 (2020) 101440
2
continues, which amplifies the generation of superoxide radicals, in-
itiating a cascade of reactive oxygen species (ROS).
The ability of NQO1 to generate cytotoxic hydroquinones has been
utilized as a strategy to target cancer cells with high NQO1 levels. To
date, β-lapachone and its derivatives are the most studied NQO1-
bioactivatable quinones, and the molecular mechanisms by which they
promote cytotoxicity have been thoroughly characterized [20–24]
(Fig. 1A). NQO1 has been proposed as a target for NSCLC therapy, as it
is overexpressed in lung tumors but not in adjacent normal tissues
[25–27]. Thus, systemic delivery of β-lapachone would spare healthy
lung tissue while inducing robust cytotoxicity in tumor cells. Although
β-lapachone has been tested in phase 1 and 2 clinical trials for advanced
solid tumors as the analogs ARQ 501 and ARQ 761, none of the clinical
trials designed to date have been focused on lung cancer patients.
Remarkably, a large fraction of NSCLC with high NQO1 also harbor
sustained NRF2 activation, which in turn could hinder the cytotoxic
effects of β-lapachone through the active scavenging of ROS. Therefore,
although high levels of NQO1 could be exploited with a therapeutic
intent in NRF2/KEAP1 mutant cancer cells, it is unclear whether ac-
tions of NRF2 could limit β-lapachone efficacy. In this study, we aim to
clarify whether NQO1 represents a druggable strategy for NRF2/KEAP1
mutant NSCLC or, conversely, these alterations promote resistance to β-
lapachone.
2. Results
2.1. Aberrant activation of NRF2 in NSCLC promotes resistance to B-
lapachone
We compared the mRNA levels of NQO1 in healthy lung tissue,
adenocarcinoma (LuAD) and squamous cell carcinoma (LuSC) patients
using the TGCA dataset (Fig. 1B, Table 1 and Table 2). NQO1 expres-
sion in lung tumors was further subdivided according to the NRF2/
KEAP1 mutational state. Both LuAD and LuSC tumors had significantly
higher NQO1 levels compared to normal lung tissue. Further, tumors
harboring NRF2/KEAP1 mutations displayed significantly higher ex-
pression of NQO1 than those lacking mutations in this pathway, con-
sistent with the direct transcriptional regulation of NQO1 by NRF2
[28]. Remarkably, a number of KEAP1WT NSCLC tumors exhibited
elevated NQO1 levels, suggesting that NQO1 overexpression in KEAP1/
NRF2WT tumors can also result from alternative mechanisms of NRF2
activation (i.e. epigenetic silencing of KEAP1 [29,30], oncogenic acti-
vation of NRF2 [31]) or through NRF2-independent mechanisms.
To examine the influence of KEAP1/NRF2 mutations on NSCLC
response to β-lapachone treatment, we assessed the cytotoxic efficacy of
β-lapachone in a panel of sixteen NSCLC cell lines, seven of which
harbor characterized inactivating mutations of KEAP1 (Fig. 1C, S1A). In
line with the mRNA data of LuSC and LuAD patients, KEAP1MUT cell
lines displayed uniformly high NQO1 protein levels, while protein le-
vels of NQO1 in KEAP1WT cells were highly variable. To determine the
range of doses of β-lapachone that promote cell death in a NQO1-de-
pendent manner, cells were treated with increasing concentrations of β-
lapachone alone or in combination with the NQO1 inhibitor dicoumarol
[32,33] (Fig. 1D, Fig. S1B). Additionally, we included in the study Calu-
3 cells, which harbor a polymorphic variant of NQO1 (NQO1*3) that
results in 95% lower enzyme levels [27,34,35] (Fig. S1C). To re-
capitulate β-lapachone in vivo half-life conditions [36], cells were
treated with β-lapachone for 2 h and cell viability was analyzed 48 h
after treatment. Our results showed that doses ranging from 1 to 6 μM
induced cell death in a dose-dependent and NQO1-specific manner.
Remarkably, KEAP1 mutation conferred resistance to β-lapachone
treatment (Fig. 1D).
To test the ability of KEAP1WT and KEAP1MUT cell lines to promote
redox cycling of β-lapachone, we monitored the oxygen consumption
rate (OCR) using the seahorse bioanalyzer. Basal OCR was monitored
prior injection of β-lapachone, and OCR was followed for 2 h after β-
lapachone addition. To validate whether changes in the OCR were a
consequence of NQO1-dependent redox cycling of β-lapachone, we also
monitored the OCR of cells co-treated with β-lapachone and dicou-
marol. Treatment with β-lapachone resulted in a significant increase of
the OCR in both KEAP1WT and KEAP1MUT cells, which was precluded by
the addition of dicoumarol (Fig. 1E). Further, there was no significant
difference in the OCR between KEAP1WT and KEAP1MUT cells after β-
lapachone treatment, indicating that protein levels of NQO1 in
KEAP1WT NSCLC cells are not limiting for redox cycling of β-lapachone.
Hence, both KEAP1WT and KEAP1MUT cancer cells are capable of NQO1-
dependent redox cycling of β-lapachone at comparable rates.
To determine whether β-lapachone resistance was NRF2-dependent,
H1299 cells (KEAP1WT) were infected with virus encoding for an in-
activating mutation of KEAP1 (C273S) or a gain-of function NRF2
mutation (T80K), to promote the aberrant activation of NRF2
[7,37,38]. In agreement with our previous findings, overexpression of
KEAP1C273S and NRF2T80K but not KEAP1WT led to the accumulation of
NRF2, which promoted resistance to β-lapachone exposure (Fig. 1F).
Consistently, NRF2 silencing by shRNAs markedly reduced resistance to
β-lapachone in H460 cells (KEAP1MUT) (Fig. 1G). Additionally, we
compared the β-lapachone sensitivity of NRF2-knockout A549 cells
[39] infected with a control vector or with virus coding for NRF2 ex-
pression (Figs. S1D and S1E). In agreement with our previous data,
NRF2-knockout cells exhibited increased sensitivity to β-lapachone
compared to cells reconstituted for NRF2 expression. Collectively, these
results indicate that aberrant activation of NRF2 in KEAP1 mutant lung
cancer cells confers resistance to β-lapachone exposure.
2.2. Activation of NRF2 promotes active scavenging of β-lapachone-induced
ROS and attenuates DNA damage
Given the established role of NRF2 in protection against ROS
through the transcriptional regulation of antioxidant enzymes, we
evaluated whether KEAP1MUT cells harbor an increased capacity to
detoxify β-lapachone-induced ROS. We monitored ROS generation after
β-lapachone exposure in our panel of NSCLC cell lines using the
fluorogenic probe CellROX Green, as previously described [40]
(Fig. 2A). We found that KEAP1WT cells displayed a significantly higher
fold-change of ROS after 1-h of β-lapachone treatment compared to
KEAP1MUT. To confirm whether β-lapachone promotes cell death via
induction of ROS, we supplemented the media with exogenous catalase
to increase the antioxidant capacity of the cells (Fig. 2B). Consistent
with prior studies [22,41], addition of exogenous catalase abrogated β-
lapachone-induced cell death. Next, we assessed whether KEAP1MUT
cells were protected against β-lapachone-induced DNA damage
[27,40]. We monitored levels of phosphorylated H2A.X (γ-H2AX), a
sensitive molecular marker of DNA damage. We observed a time-de-
pendent accumulation of DNA damage in H1299 cells (KEAP1WT),
while A549 cells (KEAP1MUT) did not exhibit increased γ-H2AX fol-
lowing 2-h treatment with 3 μM β-lapachone (Fig. 2C). We extended
these analyses to a larger panel of cell lines, and we found that
KEAP1WT cells, but not KEAP1MUT cells, accumulated γ-H2AX following
β-lapachone exposure (Fig. 2D). Accordingly, ectopic expression of
KEAP1C273S or NRF2T80K in H1299 cells also promoted resistance to β-
lapachone-induced DNA damage and decreased accumulation of ROS
(Fig. 2E, F and S2A).
We next assessed whether depletion of NRF2 could exacerbate β-
lapachone-induced DNA damage in KEAP1MUT cells (Fig. 2G). Indeed,
shRNA-mediated silencing of NRF2 in H460 and HCC15 cells increased
γ-H2AX levels following β-lapachone exposure. Lastly, we interrogated
ROS and DNA damage levels in NRF2-KO A549s infected with NRF2WT
or an empty control vector after β-lapachone treatment (Figs. S2B and
S2C). Consistently, A549 NRF2-knockout cells exhibited greater pro-
duction of ROS and accumulation of DNA damage markers compared to
cells expressing NRF2. Together, these results demonstrate that con-
stitutive activation of NRF2 in NSCLC protects cells from β-lapachone
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exposure by decreasing ROS-mediated DNA damage.
2.3. Inhibition of thioredoxin-dependent systems but not catalase and
glutathione overcome NRF2-mediated resistance to β-lapachone
To sensitize KEAP1MUT lung cancer cells to β-lapachone treatment,
we sought to identify and inhibit key NRF2-regulated antioxidant
pathways. Given the major role of hydrogen peroxide in mediating β-
lapachone toxicity, we tested whether inhibition of individual peroxide
detoxification systems could overcome β-lapachone resistance (Fig.
S3A). First, we tested the relevance of catalase in the sensitivity to β-
lapachone by using shRNAs (Fig. 3A and B). We observed that depletion
of catalase did not affect the β-lapachone sensitivity of NSCLC cells,
regardless of KEAP1 mutational status. Of note, we found that
H460 cells did not express detectable catalase protein (Fig. 3B, S3B).
NRF2 is a major upstream transcriptional regulator of enzymes
(caption on next page)
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involved in the thioredoxin (TXN)- and glutathione (GSH)-dependent
antioxidant systems, which share certain redundancy in detoxifying
hydrogen peroxide. We tested whether individual inhibition of the
thioredoxin - or glutathione-dependent systems could overcome NRF2-
mediated resistance to β-lapachone. To inhibit glutathione synthesis,
we used buthionine sulfoximine (BSO), a well-characterized inhibitor of
glutamate-cysteine ligase (GCL) [42]. Twenty-four-hour treatment with
100 or 200 μM of BSO depleted>95% of the total pool of glutathione
(Fig. S3C). To inhibit the TXN-dependent system, cells were treated
with 1–5 μM auranofin, a pan-thioredoxin reductase (TXNRD) inhibitor
for 2 h [43]. We observed a dose-dependent inhibition of both the cy-
tosolic and mitochondrial TXN-dependent systems in KEAP1WT cells, as
seen by oxidation of peroxiredoxin 1 and 3 (Fig. S3D). Interestingly,
KEAP1MUT cell peroxiredoxins were resistant to oxidation, and
KEAP1WT NSCLC cells are more sensitive to auranofin-induced cell
death in the absence of exogenous oxidants (Fig. S3E). We next ex-
amined the effect of these inhibitors on β-lapachone sensitivity. De-
pletion of glutathione did not increase the sensitivity to β-lapachone
treatment, while auranofin significantly increased β-lapachone-induced
cell death and DNA damage in KEAP1MUTcells (Fig. 3C and D). Simi-
larly, auranofin but not BSO increased sensitivity of KEAP1WT cells to β-
lapachone exposure (Fig. 3E).
These data suggest that although inhibition of the TXN-dependent
system increases sensitivity of KEAP1MUT cells to β-lapachone, the in-
herent reinforcement of this antioxidant pathway in KEAP1MUT cells
might represent a challenge in vivo. Further, single inhibition of the
glutathione or catalase it is not sufficient to increase sensitivity to β-
lapachone treatment, suggesting that inhibition of these pathways is
compensated by other antioxidant mechanisms.
2.4. Inhibition of SOD1 potentiates β-lapachone anti-tumor efficacy in
KEAP1/NRF2MUT NSCLC
The inherent redundancy in the hydrogen peroxide detoxification
systems represents a major challenge to sensitize KEAP1MUT cells to
ROS generators, as inhibition of one of these pathways may be com-
pensated by other antioxidant enzymes. In contrast, SOD1 has a unique
role in catalyzing the dismutation of cytosolic superoxide radicals
generated by β-lapachone (Fig. 4A). Given this unique role of SOD1, we
interrogated the effects of SOD1 inhibition on β-lapachone efficacy. We
infected KEAP1MUT cells with virus coding for shRNAs against SOD1 or
a non-targeting shRNA (Fig. S4A). Depletion of SOD1 markedly in-
creased β-lapachone-mediated cell death in KEAP1MUT cell lines and
increased DNA damage (Fig. 4B and C, S4B). Importantly, β-lapachone
treatment did not change SOD1 activity (Fig. S4C).
To validate these findings, we sough to test the effect of
pharmacological inhibition of SOD1 on β-lapachone efficacy. However,
direct inhibitors of SOD1 that have been shown efficacy in cell-based
assays or in vivo are lacking. The cytosolic (SOD1) and the extracellular
(SOD3) superoxide dismutases require copper and zinc to function,
while the mitochondrial isoform (SOD2) relies on manganese. Thus,
indirect inhibition of SOD1 can be achieved through copper chelation
[44,45], while the mitochondrial SOD activity should remain intact.
First, we validated whether we could achieve SOD1 inhibition in
cell culture using the copper chelator ATN-224 (Fig. S4D). We observed
that most of SOD1 activity was inhibited after 24-h treatment using
2.5–5 μM. As expected, copper chelation did not affect SOD2 activity.
Inhibition of SOD1 resulted in increased sensitivity of KEAP1MUT cells
to β-lapachone-mediated cell death and DNA damage (Fig. 4D and E).
Of note, SOD1 inhibition had little to no effect in KEAP1WT cells
(Fig. 4D). We also examined the protein levels and activity of SOD1
across our panel of NSCLC cells to evaluate whether KEAP1MUT cells
have higher capacity to detoxify cytosolic superoxide (Fig. S4E). KEAP1
mutant cells did not exhibit significantly higher levels of SOD1, sug-
gesting that inactivation of KEAP1 does not confer a reinforced capacity
to detoxify cytosolic superoxide radicals through SOD1 upregulation.
To directly interrogate whether NRF2 regulates SOD1 levels/activity,
we infected KEAP1MUT cells with shRNAs against NRF2 and monitored
SOD1 protein levels and its enzymatic activity (Figs. S4F and S4G).
Depletion of NRF2 was accompanied by reduced protein levels of the
well-characterized NRF2 targets NQO1, TXN and TXNRD1 (Fig. S4F),
while SOD1 protein levels were unchanged. Similarly, we did not ob-
serve any changes in SOD1 activity following NRF2 depletion (Fig.
S4G). These results suggest that hyperactivation of NRF2 does not alter
SOD1 protein levels or activity.
To confirm whether copper chelation sensitizes KEAP1MUT cells
through SOD1 inhibition, A549 cells were engineered to express an
Escherichia coli manganese-dependent superoxide dismutase enzyme
(SodA) to rescue SOD activity. Importantly, SodA expression sig-
nificantly rescued the effects of copper chelation on β-lapachone
treatment (Fig. 4F and G). Altogether, these data demonstrate that in-
hibition of SOD1 selectively increases β-lapachone efficacy in
KEAP1MUT NSCLC cells.
3. Discussion
Aberrant NRF2 activation promotes resistance to therapeutics that
rely on the production of ROS, including multiple chemotherapeutics
and radiation therapy. In this study, we find that NRF2 activation also
promotes resistance to the NQO1-activatable prodrug β-lapachone,
which relies on the generation of superoxide for its efficacy. While di-
rect NRF2 inhibition could potentially reverse this resistance, NRF2
Fig. 2. Activation of NRF2 promotes active scavenging of β-lapachone-induced ROS and attenuates DNA damage.
(A) A panel of KEAP1 mutant and KEAP1 wild-type NSCLC cell lines were exposed to 3 μM of β-lapachone for 1 h. Relative increase of ROS was measured using the
green fluorescent probe CellROX green by flow cytometry. KEAP1WT cells: H1299, H1581, H1975, H2087, H2347, H441. KEAP1MUT cells: A549, H1792, H1944,
H2172, H460, HCC15. Data presented as mean ± S.D. (B) Cell survival analyses of NSCLC cell lines exposed to vehicle control, β-lapachone alone or co-treated with
1000 U catalase/well (96-well plate) for 2 h. Surviving cells were stained with crystal violet 48 h after treatment. KEAP1WT cells: H1299, H1581, H441, H2347,
H2087. KEAP1MUT cells: A549, H1944, H460, HCC15, H1792, H322. Data presented as mean ± S.D. (C) A549 and H1299 cells, KEAP1 mutant and wild-type
respectively, were exposed to 3 μM of β-lapachone for 0, 15, 60 and 120 min, after which cells were collected and protein levels of NRF2, total H2AX (loading
control), and the DNA damage marker γ-H2AX (pS139) were assessed by western blotting. (D)Western blot analyses of nuclear extracts of a panel of KEAP1 wild-type
(WT) or mutant (MUT) NSCLC cell lines. Cells were treated with 3 μM of β-Lapachone for 2 h. Protein levels of NRF2, total H2AX (loading control), and the DNA
damage marker γ-H2AX (pS139) were assessed by western blotting. KEAP1WT cells: H1299, H1581, H1975, H2347. KEAP1MUT cells: A549, H1944, H460, HCC15. (E)
DNA damage assessment of H1299 cells (KEAP1 WT) infected with an empty vector (Control) or a virus coding for the expression of NRF2 T80K. Left, cells were
exposed to 2, 3 or 4 μM of β-lapachone. Protein levels of NRF2, NQO1, total H2AX (loading control), Tubulin (loading control) and the DNA damage marker γ-H2AX
(pS139) were assessed by western blotting. See Supplementary Fig. 2A. (F) H1299 cells (KEAP1 WT) were infected with an empty vector (Control) or a virus coding
for the expression of NRF2 T80K, KEAP1 wild-type or KEAP1 C273S. Cells were exposed to 1–4 μM of β-lapachone for 1 h and resulting fluorescent signal of the probe
CellROX green was measured by flow cytometry. P-values were calculated using one-way ANOVA statistical test followed by the multiple comparison Dunnett's test
to compare between treatment groups. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data presented as mean ± S.D. (G) H460 and HCC15 cells
(KEAP1 MUT) infected with virus coding for shRNAs against NRF2 (shNRF2) or an shRNA control were treated with the indicated concentration of β-lapachone for
2 h, after which protein levels of NRF2, total H2AX (loading control), Tubulin (loading control) and the DNA damage marker γ-H2AX (pS139) were assessed by
western blotting. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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inhibitors identified to date either lack specificity or potency. Further,
the effects of NRF2 whole-body inhibition as anti-tumor strategy re-
main unclear, as NRF2 activity in necessary for normal functioning of
immune cells [46,47].
Consequently, we have evaluated whether inhibition of the cellular
antioxidant systems can reverse the resistance of NRF2 active cells to
ROS. We find that inhibitors of the TXN-dependent peroxide detox-
ification system and SOD1, but not glutathione or catalase depletion,
can reverse the resistance of KEAP1MUT cells to β-lapachone.
Surprisingly, we find that KEAP1MUT cells were highly resistant to
Fig. 3. Inhibition of the TXN-dependent system but not GSH and catalase enhances sensitivity to β-lapachone treatment.
(A) Assessment of β-lapachone sensitivity of NSCLC cell lines infected with shRNA against catalase (shCAT) or non-targeting control shRNA (shCTL). (B) Western
blotting analysis of CAT and Actin (loading control) to validate the efficacy of the shRNAs against catalase. (C) Survival assays of a panel of KEAP1MUT cells exposed
to β-lapachone alone or in combination with BSO (24 h pre-treatment) or auranofin (2 h co-treatment) to specifically inhibit the glutathione, and thioredoxin-
dependent systems, respectively. Cells were fixed and stained with crystal violet 48 h after treatment. (D) DNA damage assessment of a panel of KEAP1 mutant cells
exposed to β-lapachone alone or in combination with 3 or 5 μM of auranofin for 2 h. Protein levels of total H2AX (loading control) and the DNA damage marker γ-
H2AX (pS139) were assessed by western blotting. (E) Survival assays of KEAP1WT cells exposed to β-lapachone alone or in combination with BSO (24 h pre-
treatment) or auranofin (2 h co-treatment). Surviving cells were fixed and stained 48 h after treatment. For A, C, and E, data are presented as mean ± S.D. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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auranofin compared to KEAP1WT cells, which raises a concern about the
toxicity of the required auranofin doses to healthy tissues. The re-
sistance of KEAP1MUT cells is likely explained by the redundancy of the
thioredoxin- and glutathione-dependent antioxidant systems, which can
both detoxify H2O2 and protect from excessive oxidation. Indeed, even
at the highest doses of auranofin, KEAP1MUT cells exhibited no perox-
iredoxin oxidation in the absence of exogenous oxidants. This re-
dundancy of the antioxidant program, particularly in cancer cells, re-
presents a major challenge [48]. Although concomitant inhibition of
the GSH and the TXN-dependent systems has been shown to abolish
such redundancy in vitro, this strategy appears to be highly toxic and
potentially lethal in vivo. Elias Arnér's laboratory previously reported
that combination of auranofin and BSO in mice, at concentrations that
are tolerable as single agents, was lethal after the first round of ad-
ministration [49].
While previous studies demonstrated an important role for H2O2 in
mediating β-lapachone cytotoxicity, we uncovered a surprising role for
SOD1 in the protection against cell death in KEAP1MUT cells. The
(caption on next page)
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selectivity of SOD1 inhibition for KEAP1MUT cells may be a consequence
of the enhanced peroxide detoxification capacity of these cells, while
KEAP1WT cells may be equally sensitive to both peroxide and super-
oxide. Importantly, our results suggest that antioxidant inhibition may
sensitize NRF2/KEAP1 mutant cells to other ROS-generating ther-
apeutics to which these cells are generally resistant. In agreement with
our findings, a recent study found that SOD1 deletion or modulation of
copper availability sensitized Jurkat cells to the superoxide generating
compound paraquat [50]. Interestingly, SOD1 inhibition alone could
target NSCLC cells in a study using A549 and H460 cells, which are
KEAP1 mutant [51]. Authors also found that SOD1 inhibition was sy-
nergistic with glutathione depletion, suggesting that alternative com-
binations to inhibit the antioxidant capacity of KEAP1 mutant cells may
be possible.
Auranofin and ATN-224 join the growing list of agents that can
sensitize cells to β-lapachone. These agents converge on DNA damage
and repair (PARP and XRCC1) [27,40], NAD + availability (NAMPT)
[52], and ROS (GLS1 inhibition) [53]. However, cautions should be
taken when considering combination of β-lapachone and inhibition of
antioxidant systems for in vivo studies, as it might increase toxicity.
Indeed, β-lapachone has been shown to induce toxicity in red blood
cells due to the production of methemoglobin [54,55], which might
represent a major limitation when combined with SOD1 or TXNRD
inhibitors. Recently, more potent NQO1-activatable compounds, in-
cluding the deoxynyboquinones (DNQs) have shown equivalent efficacy
to β-lapachone at 6-fold lower dose [22]. Isobutyl-deoxynyboquinone
(IB-DNQ) is being developed for clinical use [56], and lacks the issues
with stability, solubility and red blood cell toxicity that β-lapachone
demonstrates. Further, Napabucasin, a well-characterized STAT3 in-
hibitor currently in clinical trials [57,58], has also been shown recently
to induce cytotoxicity via NQO1-dependent redox cycling and, to a
lesser extent, through cytochrome P450 oxidoreductase one-electron
reduction [59]. In agreement with our data, authors also observed that
depletion of TXNRD1 also conferred sensitivity to Napabucasin in
pancreatic cancer cells. Our results suggest KEAP1MUT cells would be
resistant to IB-DNQ and Napabucasin as well, and KEAP1/NRF2 mu-
tation status should be considered in addition to NQO1 levels when
predicting in vivo response to these agents.
4. Materials and methods
Reagents and chemicals. β-Lapachone and dicoumarol were a gift
from Professor David Boothman. Nitrotetrazolium Blue chloride
powder (N6639), riboflavin (R7649), Auranofin (A6733-10MG) and
Catalase from bovine liver (C1345) were all obtained from Sigma
Aldrich. L-Buthionine-(S,R)-Sulfoximine (BSO) was obtained from
Cayman Chemical (14484) or from Sigma Aldrich (B2515-500MG).
ATN-224 was purchased from Cayman Chemical (23553). N-
Ethylmaleimide was purchased from Chemimpex.
Cell culture and reagents. Parental NSCLC cell lines were pre-
viously described (DeNicola et al., 2015). NRF2-KO A549 cells were
obtained from Dr. Laureano de la Vega (Torrente et al., 2017). Cell lines
were routinely tested and verified to be free of mycoplasma (MycoAlert
Assay, Lonza). All lines were maintained in RPMI 1640 media (Hyclone
or Gibco) supplemented with 5–10% FBS without antibiotics at 37 °C in
a humidified atmosphere containing 5% CO2 and 95% air. Lenti-X 293T
cells were obtained from Clontech, and maintained in DMEM media
(Hyclone or Gibco) supplemented with 10% FBS.
Antibodies. The following antibodies were used: NRF2 (Cell
Signaling Technologies, D1Z9C, Cat #12721), NQO1 (Sigma Aldrich,
Cat# HPA007308), β-actin (Thermo Fisher, clone AC-15, Cat # A5441),
α-tubulin (Santa Cruz, TU-02, Cat #sc-8035), Total Histone H2A.X (Cell
Signaling Technologies, D17A3, Cat #9718), Gamma Histone H2A.X
(Cell Signaling Technologies, 20E3, Cat #7631S), KEAP1 (Millipore
Sigma, Cat# MABS514), SOD1 (Cell Signaling Technologies, 71G8, Cat
#4266), Catalase (Cell Signaling Technologies, D4P7B, Cat #12980S),
Flag Tag (Cell Signaling Technologies, M2, Cat# 14793S), HA-Tag (Cell
Signaling Technologies, C29F4, Cat #3724), Prdx3 (Abcam, Cat
#ab73349), Prdx1 (Cell Signalling, D5G12, Cat# 50-191-580)
Plasmids. shRNAs against SOD1, NRF2 and catalase in the pLKO.1
backbone were purchased from Dharmacon. shSOD1(1)
TRCN0000039809, shSOD1 (2) TRCN0000039812, shSOD1 (3)
TRCN0000039808. shNRF2(1) TRCN0000007555 and shNRF2 (2)
TRCN0000281950 were previously described [60]. shCAT
TRCN0000061756. The shRNA control was purchased from Sigma-Al-
drich (#SHC002). pLX317-NRF2 and pLX317-NRF2T80K were obtained
from Dr. Alice Berger [61] and the pLX317 empty control vector was
generated by site-directed mutagenesis as previously described [62].
SodA: The cDNA encoding for the MnSOD (Gene name: sodA) of Es-
cherichia coli (strain K12) containing a c-terminal Influenza He-
magglutinin (HA) reporter tag was cloned into the backbone pLX317-
empty using the In-Fusion cloning kit (Clontech). The backbone was cut
with BamHI and EcoRI. KEAP1 WT and KEAP1 C273S vectors were
obtained from Dr. Christian Metallo [63] (Fig. 1F) and KEAP1 proteins
were subcloned into the pLX317-empty backbone (Fig. 2F and S2A)
between the NheI and EcoRV sites.
Stable cell line generation. Stable cell lines were generated via
lentiviral transduction. For lentivirus production, Lenti-X 293T cells
(Clontech) were transfected at 90% confluence with JetPRIME
(Polyplus) or Polyethylenimine (PEI). Packaging plasmids pCMV-dR8.2
dvpr (addgene # 8455) and pCMV-VSV-G (addgene #8454) were used.
Cells were transduced for 6 h by recombinant lentiviruses in growth
Fig. 4. Inhibition of the copper-zinc superoxide dismutase (SOD1) potentiates β-lapachone anti-tumor efficacy in NSCLC in vitro.
(A) Schematic representation of the potential role of SOD1 in the detoxification of β-lapachone-induced ROS. (B) Survival assays of a panel of KEAP1 mutant NSCLC
cells infected with virus encoding for shRNAs against SOD1 (1, 2) or with a control shRNA (shCTL). NSCLC cells were treated with vehicle (0.012% DMSO) or with
3 μM β-lapachone for 2 h. Cell viability was assessed 48 h after treatment. One-way ANOVA statistical test was performed, followed by the multiple comparison
Dunnett's test. H1944 shCTL vs shSOD1(1) = 0.0001 (****), shCTL vs shSOD1 (2) = 0.0003 (***). A549 shCTL vs shSOD1(1) = 0.0001 (****), shCTL vs shSOD1
(2) = 0.0007 (***). H460 shCTL vs shSOD1(1) = 0.0133 (*), shCTL vs shSOD1 (2) = 0.0128 (*). HCC15 shCTL vs shSOD1(1) = 0.0039 (**), shCTL vs shSOD1
(2) = 0.0005 (***). (C) KEAP1 mutant cells were infected with virus encoding for shRNAs against SOD1 (1, 3) or with an shRNA control (shCTL). Cells were treated
with 3 μM β-lapachone and protein levels of total H2AX (loading control), SOD1 and the DNA damage marker γ-H2AX (pS139) were assessed by western blotting 2 h
after treatment. (D) A panel of KEAP1 mutant (top) and KEAP1 WT (bottom) NSCLC cells were treated for 24 h with vehicle (0.05% DMSO) or with 2.5 or 5 μM of
ATN-224, after which cells were treated with β-lapachone for 2 h in ATN-224 or vehicle containing medium. Fresh media was added after treatment to allow for
SOD1 reactivation. Cell viability was assessed 48 h after treatment using crystal violet. (E) NSCLC cells were treated for 24 h with vehicle (0.05% DMSO) or with 2.5
or 5 μM of ATN-224, after which cells were treated with β-lapachone for 2 h in ATN-224 or vehicle containing medium. Protein levels of total H2AX (loading control)
and the DNA damage marker γ-H2AX (pS139) were assessed by western blotting. (F) A549 cells were infected with virus coding for the expression of E. coli MnSOD
(SodA) or an empty vector (control). Cells were pre-treated for 24 h with ATN-224 (2.5 or 5 μM) or vehicle (0.05% DMSO), after which cells were exposed to 2μM of
β-lapachone (alone or in combination with the indicated concentrations of ATN-224) for 2 h. Surviving cells were stained with crystal violet 48 h after treatment. (G)
A549 SodA or control were pre-treated for 24 h with ATN-224 (5 μM) or vehicle, after which cells were exposed to the indicated concentrations of β-lapachone (alone
or in combination of ATN-224) for 2 h. Protein levels of SodA (HA-tag), Tubulin (loading control), total H2AX (loading control), and the DNA damage marker γ-H2AX
(pS139) were assessed by western blotting. For B, D, and F, data are presented as mean ± S.D. (For interpretation of the references to colour in this figure legend, the
reader is referred to the Web version of this article.)
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media using polybrene (8 μg/ml). Twenty-four hours after transduction,
puromycin (1 μg/ml) was added to the growth medium for 72 h to
select for infected cells.
Cell viability assays. NSCLC cells were seeded in 96-well plates at
a density of 2,500–5,000 cells/well in a 200 μl final volume. The fol-
lowing day, the media was replaced with 150 μl of fresh media con-
taining the indicated concentrations of β-lapachone or vehicle (≤0.1%
DMSO) for 2 h, after which media was replaced. Two hours after
treatment, medium was replaced by 200 μl fresh medium. Cell viability
was assessed 48 h after treatment with CellTiter-Glo (Promega) or
crystal violet staining. To stain surviving cells with crystal violet, cells
were washed in ice-cold PBS, fixed with 4% paraformaldehyde, stained
with crystal violet solution (0.1% Crystal Violet, 20% methanol), wa-
shed with H2O and dried overnight. Crystal violet was solubilized in
10% acetic acid for 30 min and the OD600 was measured. Relative cell
number was normalized to vehicle treated cells.
For experiments using the copper chelator ATN-224, cells were pre-
treated with 1–5 μM of ATN-224 for 24 h prior β-lapachone treatment.
To ensure that no copper was added back with the media when cells
were treated with β-lapachone, additional ATN-224 containing medium
was prepared the day before β-lapachone treatment and stored at 4°C.
After 24 h, β-lapachone was prepared in ATN-224 containing medium
and 150 μl were dispensed in each well. Similarly, cells were pre-
treated for 24 h with 100–200 μM of BSO prior β-lapachone exposure,
which was prepared in BSO containing media to prevent the recovery of
glutathione. Auranofin was added to the media in combination with β-
lapachone for 2 h.
Protein extraction and Immunoblotting. Lysates were prepared
in RIPA lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate) containing
protease and phosphatase inhibitors. To assess total/gamma-H2A.X
levels in whole cell lysates, cells were lysed in boiling 1% w/v SDS RIPA
lysis buffer supplemented with phosphatase and protease inhibitors.
Cells were seeded in 6-well plates at 70–90% confluence. After drug
treatment (β-lapachone ± ATN-224 or auranofin) cells were washed in
PBS and 300 μl of pre-warmed lysis buffer (90°C) was directly added to
the wells. Cell lysates were transferred to a microcentrifuge tubes, in-
cubated at 90°C for 5 min, followed by sonication to shred the DNA in a
water bath sonicator (Diagenode). Samples were centrifuged at 13,000
x rpm for 15 min at 4°C to precipitate the insoluble fraction. The su-
pernatant was transferred to a clean Eppendorf tube. Alternatively,
total/gamma-H2A.X levels were monitored in nuclear extracts (see
protocol below). Cell lysates were mixed with 6X sample buffer con-
taining β-ME and separated by SDS-PAGE using NuPAGE 4–12% Bis-
Tris gels (Invitrogen), followed by transfer to 0.45μm Nitrocellulose
membranes (GE Healthcare). The membranes were blocked in 5% non-
fat milk in TBS-T, followed by immunoblotting.
Nuclear isolation. Cells were plated in 6-cm dishes at 70–90%
confluence (5 × 105 cells/well). The following day, cells were washed
with ice-cold PBS, collected in 1 ml of ice-cold PBS, transferred to mi-
crocentrifuge tubes, and subjected to centrifugation at 13,000 × rpm
for 1 min at 4°C. The cell pellet was resuspended in 400 μl of ice-cold of
the low-salt buffer A (10 mM HEPES/KOH pH 7.9, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA and protease/phosphatase inhibitors). After in-
cubation for 10 min on ice, 10 μl of 10% NP-40 was added and cells
were lysed by gently vortexing. The homogenate was centrifuged for
10 s at 13,200 rpm. The supernatant was collected as the cytoplasmic
fraction while the pellet containing the cell nuclei was washed 4 times
in 400 μl buffer A. Cell nuclei was lysed in 100μl high-salt buffer B
(20mM HEPES/KOH pH7.9, 400mM NaCl, 1mM EDTA, 1mM EGTA and
protease/phosphatase inhibitors). The lysates were sonicated and cen-
trifuged at 4 °C for 15 min at 13,200 rpm. The supernatant representing
the nuclear fraction was collected and protein concentration of both
fractions was determined using the DC protein assay (Biorad). Cytosolic
and nuclear fractions were further diluted to the desired protein con-
centration using the corresponding lysis buffers. One volume of 5X
sample SDS loading buffer (250 mM Tris-Cl [pH 6.8], 10% [v/v] SDS,
40% [v/v] glycerol, and 0.1% [w/v] bromophenol blue, 15% [v/v] β-
mercaptoethanol) was added to 4 volumes of the lysate and subjected to
SDS-PAGE.
In-gel SOD activity assay. Cells were plated in 35 mm diameter
cell culture dishes at a density of 5 × 105 if assayed the following day
or 3.5 × 105 cells/well if 24 h of ATN-224 pre-treatment was required.
Cells were collected by scraping with ice-cold PBS and lysed on ice for
30 min in 100 μl of SOD lysis buffer (8.96 mM Na2HPO4, 0.96 mM
NaH2PO4, 0.1% Triton X-100, 5 mM EDTA, 5 mM EGTA, 50 mM NaCl,
10% Glycerol). Samples were centrifuged for 15 min at 13,000 x rpm at
4 °C, and supernatant transferred to a microcentrifuge tube. Protein
concentration was determined using the DC protein Assay (Biorad).
Protein samples were diluted to 0.7–1 μg/μl using the SOD lysis buffer
and 1/5th volume of 5x native loading dye [0.31 M Tris pH 6.8, 0.05%
bromophenol blue (w/v), 50% glycerol (v/v)]. Samples were subjected
to native polyacrylamide gel electrophoresis (7.5%) at 90V for 2 h at
4 °C in a buffer containing 25 mM Tris, 192 mM glycine. The gel was
stained in SOD staining solution (0.22 M K2HPO4, 0.02 M KH2PO4, 1%
[w/v] Riboflavin, 1.3% [w/v] Nitro blue tetrazolium and 0.1% TEMED)
in the dark for 1 h, after which the gel was washed in dH2O and exposed
to light until developed to dark blue/black (1 h approximately).
Achromatic bands correspond to SOD1 and SOD2.
Reactive oxygen species measurement. Reactive oxygen species
were measured using the CellROX green reagent (Thermofisher) ac-
cording to the manufacturer's instructions. In short, cells were plated in
24-well plates at 70% confluence. The following day, cells were treated
with the indicated concentrations of β-lapachone in a 400 μl/well final
volume for 30 min at 37 °C. CellROX green reagent was added to a final
concentration of 5 μM to the cells without replacing the media, and
incubated for additional 30 min at 37 °C. Cells were washed in PBS,
trypsinized and transferred to microcentrifuge tubes. The cell suspen-
sion was centrifuged for 20 s at 13,000 x rpm, and resuspended in
300 μl of ice-cold PBS. The Green fluorescence of dye-loaded cells was
determined by flow cytometry using the FACSCalibur flow cytometer
(BD Biosciences) and the acquisition software CellQuest Pro. The mean
fluorescence intensity of 10,000 discrete events was calculated for each
sample.
Glutathione measurement. H1944 and HCC15 cells were seeded
on flat, round bottomed 96-well plates at a density of 1 × 104 cells/
well. The following day, media was replaced with media containing
100–200 μM of BSO or fresh media (negative control). The following
day, the GSH-Glo™ Glutathione Assay (Promega, Cat# V6911) was used
to measure the intracellular reduced glutathione pool (GSH). Data were
normalized by percentage relative to the control non-treated sample.
Redox western blotting. The protocol for determining the ratio of
reduced and oxidized peroxiredoxin 1 and 3 was adapted from Prof.
Mark Hampton's lab [64]. One-day prior to the assay, cells were seeded
in 6-well plates at 70–90% confluence (~5 × 105 cells/well). The
following day, cell culture media was replaced with 1ml of media
containing 1, 3 or 5 μM of auranofin or fresh medium. Final DMSO
concentration was 0.013% (V/V). Two hours after treatment, media
was aspirated and cells were gently washed with 1 ml of ice-cold PBS.
1 mg/ml of bovine catalase was added to the alkylation buffer (40mM
HEPES, 50mM NaCl, 1mM EGTA, complete protease inhibitors, pH 7.4)
30 min prior collection. Immediately prior sample collection, 200 mM
of N-Ethylmaleimide (NEM) were added to the alkylation buffer and the
lysis buffer was warmed to 42 °C for 1–2 min to dissolve the NEM. To
lyse the cells, 200 μl of alkylation buffer were dispensed in each well,
followed by 10 min incubation at room temperature. A solution of 10%
CHAPS was added to the lysates to a final concentration of 1% CHAPS
(20 μl/sample). Cell lysates were transferred to a 1.5 ml micro-
centrifuge tube, samples were vortex and incubated on ice for further
30 min, followed by 15 min centrifugation at 13,000 x rpm, 4°C. The
supernatant was transferred to a clean 1.5 ml microcentrifuge tube.
These redox western samples were mixed with a 4X non-reducing buffer
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prior to separation by SDS-Page.
Analysis of NQO1 mRNA expression in patient samples. Patient
normal lung, LuAD and LuSC data mRNA data was obtained by com-
bining the data available in cBioportal and the MethHC databases.
Patient LuAD and LuAD data from The Cancer Genome Atlas (TCGA),
with associated KEAP1 mutation status (Illumina HM450 Beadchip),
was obtained from cBioPortal [65,66]. Patient IDs were matched with
the data from The Cancer Genome Atlas (TCGA) via the MethHC da-
tabase [67], and expression of NQO1 in normal lung tissue data was
included in the study.
Seahorse assay (Oxygen consumption). Seahorse assays were
performed using the Seahorse XFe96 analyzer (Agilent) according to
the manufacturer's instructions. 4 × 104 cells/well were seeded in the
seahorse XF96 cell culture microplates at a final volume of 80 μl. Sensor
cartridge was hydrated overnight in a non-CO2 37 °C incubator with
Seahorse the XF calibrant (200 μl). The following day, cell media was
changed to bicarbonate-free supplemented with 4.5 g/L glucose, 2mM
glutamine and antibiotics (penicillin/streptomycin) at a final volume of
175 μl/well. Cells were incubated for 40 min-1 hour in a non-CO2 37 °C
incubator. β-Lapachone and dicoumarol were prepared as concentrated
stocks (8X). Three baseline measurements were obtained prior to in-
jection of β-lapachone alone or in combination with dicoumarol. All the
experimental conditions contained equal amounts of β-lapachone ve-
hicle (0.016% DMSO) and dicoumarol vehicle (150 μM NaOH). After β-
lapachone/dicoumarol injections, the Oxygen Consumption Rate was
followed for 2 h (20 measurements). OCR values displayed in Fig. 1E
depict the OCR 117 min after β-lapachone ± dicoumarol injections.
Cytotoxicity assay (CellToxTM green cytotoxicity assay). H1581
cells were seeded on flat, black-walled, clear bottom 96-well plates at a
density of 1 × 104 cells/well. The following day, cells were exposed to
β-lapachone for 2 h, after which the medium was replaced by phenol-
free RPMI medium supplemented with 5% FBS and antibiotics (peni-
cillin/streptomycin) and 1X of CellTox green dye (Promega, Cat#
G8741) to a final volume of 100 μl. Fluorescent signal was monitored
by microscopy and the images shown in S1B were taken 48-h post β-
lapachone treatment.
Statistical analyses. Data were analyzed using a two-sided un-
paired/paired Student's t-test or One-way ANOVA followed by Tukey's
or Dunnett's multiple comparison tests as appropriate. GraphPad Prism
7 software was used for all statistical analyses, and values of P < 0.05
were considered statistically significant (*P < 0.05; **P < 0.01;
***P < 0.001, ****P < 0.0001).
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